<span style="margin-left: 0em;">chemotherapy</span> <span style="margin-left: 1em;">non platinum-based chemotherapy</span> <span style="margin-left: 2em;">taxanes</span> <span style="margin-left: 3em;">docetaxel <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">atezolizumab based treatment</span> <span style="margin-left: 3em;">atezolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">avelumab based treatment</span> <span style="margin-left: 3em;">avelumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">nivolumab based treatment</span> <span style="margin-left: 3em;">nivolumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">Tislelizumab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (4) progression or deaths (PFS) (4) objective responses (ORR) (4) DOR (2) deaths (OS) (extension) (1) objective responses (ORR) (extension) (1) PFS (extension) (1) TRAE leading to death (grade 5) (5) TRAE (any grade) (4) TRAE (grade 3-4) (4) TRAE leading to discontinuation (any grade) (4) STRAE (any grade) (2) AE (any grade) (2) AE leading to treatment discontinuation (any grade) (2) TRAE leading to discontinuation (grade 3-4) (2) AE (grade 3-4) (2) AE leading to death (grade 5) (2) SAE (any grade) (1) SAE (grade 3-4) (1) STRAE (grade 3-4) (1) Hypothyroidism TRAE (grade 3-4) (2) Alopecia TRAE (grade 3-4) (2) Pneumonitis TRAE (grade 3-4) (2) Fatigue TRAE (grade 3-4) (2) Diarrhoea TRAE (grade 3-4) (2) Colitis TRAE (grade 3-4) (2) Increased ALT TRAE (grade 3-4) (2) Neutropenia TRAE (grade 3-4) (2) Leucopenia TRAE (grade 3-4) (2) Decreased appetite TRAE (grade 3-4) (2) Anaemia TRAE (grade 3-4) (2) Infusion-related reactions TRAE (grade 3-4) (2) Acute kidney injury TRAE (grade 3-4) (2) Hypersensitivity TRAE (grade 3-4) (2) Peripheral oedema TRAE (grade 3-4) (1) Mucosal inflammation TRAE (grade 3-4) (1) Stomatitis TRAE (grade 3-4) (1) Hypertension TRAE (grade 3-4) (1) Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) (1) Febrile neutropenia TRAE (grade 3-4) (1) Sepsis TRAE (grade 3-4) (1) Pneumonia TRAE (grade 3-4) (1) Nausea TRAE (grade 3-4) (1) Arthralgia TRAE (grade 3-4) (1) Asthenia TRAE (grade 3-4) (1) Dyspnoea TRAE (grade 3-4) (1) Pyrexia TRAE (grade 3-4) (1) Peripheral sensory neuropathy TRAE (grade 3-4) (1) Vomiting TRAE (grade 3-4) (1) Myalgia TRAE (grade 3-4) (1) Headache TRAE (grade 3-4) (1) Increased lipase level TRAE (grade 3-4) (1) Adrenal insufficiency TRAE (grade 3-4) (1) Myocarditis TRAE (grade 3-4) (1) Peripheral neuropathy TRAE (grade 3-4) (1) Weight decreased TRAE (grade 3-4) (1) Eczema TRAE (grade 3-4) (1) Endocrine disorders TRAE (grade 3-4) (1) Pruritus TRAE (grade 3-4) (1) Rash TRAE (grade 3-4) (1) Increase AST TRAE (grade 3-4) (1) Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) (1) Erythema TRAE (grade 3-4) (1) Hepatobiliary disorders TRAE (grade 3-4) (1) Vitiligo TRAE (grade 3-4) (1) Hyperthyroidism TRAE (grade 3-4) (1) Maculopapular rash TRAE (grade 3-4) (1) Skin and subcutaneous tissue disorders TRAE (grade 3-4) (1) Gastrointestinal disorders TRAE (grade 3-4) (1) Blood creatinine increased TRAE (grade 3-4) (1) Pruritus generalised TRAE (grade 3-4) (1) Thyroiditis TRAE (grade 3-4) (1) Renal and urinary disorders TRAE (grade 3-4) (1) Diabetes TRAE (grade 3-4) (1) Decreased appetite AE (grade 3-4) (1) Diarrhoea AE (grade 3-4) (1) Asthenia AE (grade 3-4) (1) Pyrexia AE (grade 3-4) (1) Nausea AE (grade 3-4) (1) Fatigue AE (grade 3-4) (1) Back pain AE (grade 3-4) (1) Arthralgia AE (grade 3-4) (1) Stomatitis AE (grade 3-4) (1) Vomiting AE (grade 3-4) (1) Anaemia AE (grade 3-4) (1) Neutropenia AE (grade 3-4) (1) Peripheral oedema AE (grade 3-4) (1) Constipation AE (grade 3-4) (1) Cough AE (grade 3-4) (1) Febrile neutropenia AE (grade 3-4) (1) Peripheral neuropathy AE (grade 3-4) (1) Myalgia AE (grade 3-4) (1) Alopecia AE (grade 3-4) (1) Dyspnoea AE (grade 3-4) (1) Dysgeusia AE (grade 3-4) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
2 POPLAR, 2016
OAK (all population), 2016 1 CheckMate 078, 2019 1 JAVELIN Lung 200 (all population), 2018 atezolizumab alone vs. avelumab alone
0.88 [0.70; 1.09] 0.88 [0.70;1.09]atezolizumab alone vs. avelumab alone
0.88 [0.70; 1.09] atezolizumab alone vs. docetaxel
atezolizumab alone better
0.79 [0.70; 0.89] 0.79 [0.70;0.89]atezolizumab alone vs. docetaxel
atezolizumab alone better
0.79 [0.70; 0.89] atezolizumab alone vs. nivolumab alone
1.16 [0.86; 1.57] 1.16 [0.86;1.57]atezolizumab alone vs. nivolumab alone
1.16 [0.86; 1.57] avelumab alone vs. atezolizumab alone
1.14 [0.92; 1.42] 1.14 [0.92;1.42]avelumab alone vs. atezolizumab alone
1.14 [0.92; 1.42] avelumab alone vs. docetaxel
0.90 [0.75; 1.08] 0.90 [0.75;1.08]avelumab alone vs. docetaxel
0.90 [0.75; 1.08] avelumab alone vs. nivolumab alone
1.32 [0.95; 1.84] 1.32 [0.95;1.84]avelumab alone vs. nivolumab alone
1.32 [0.95; 1.84] docetaxel vs. atezolizumab alone
atezolizumab alone better
1.27 [1.12; 1.44] 1.27 [1.12;1.44]docetaxel vs. atezolizumab alone
atezolizumab alone better
1.27 [1.12; 1.44] docetaxel vs. avelumab alone
1.11 [0.93; 1.33] 1.11 [0.93;1.33]docetaxel vs. avelumab alone
1.11 [0.93; 1.33] docetaxel vs. nivolumab alone
nivolumab alone better
1.47 [1.12; 1.93] 1.47 [1.12;1.93]docetaxel vs. nivolumab alone
nivolumab alone better
1.47 [1.12; 1.93] nivolumab alone vs. atezolizumab alone
0.86 [0.64; 1.17] 0.86 [0.64;1.17]nivolumab alone vs. atezolizumab alone
0.86 [0.64; 1.17] nivolumab alone vs. avelumab alone
0.76 [0.54; 1.05] 0.76 [0.54;1.05]nivolumab alone vs. avelumab alone
0.76 [0.54; 1.05] nivolumab alone vs. docetaxel
nivolumab alone better
0.68 [0.52; 0.89] 0.68 [0.52;0.89]nivolumab alone vs. docetaxel
nivolumab alone better
0.68 [0.52; 0.89] docetaxel atezolizumab alone nivolumab alone avelumab alone Tislelizumab direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C docetaxel atezolizumab alone nivolumab alone avelumab alone Tislelizumab docetaxel --- 1.27 1.12; 1.441.47 1.12; 1.931.11 0.93; 1.33NA atezolizumab alone 0.79 0.70; 0.89--- 1.16 0.86; 1.570.88 0.70; 1.09NA nivolumab alone 0.68 0.52; 0.890.86 0.64; 1.17--- 0.76 0.54; 1.05NA avelumab alone 0.90 0.75; 1.081.14 0.92; 1.421.32 0.95; 1.84--- NA Tislelizumab NA NA NA NA ---
pathologies: 37
- treatments: 940
result logic